Preclinical Trials - An Update on Translational Research in ALS

被引:9
|
作者
Ludolph, Albert C. [1 ]
Sperfeld, A-D [1 ]
机构
[1] Univ Ulm, Dept Neurol, DE-89081 Ulm, Germany
关键词
ALS; clinical trials; translational research; Dynein/dynactin; Motor neuron disease; Motor neuron diseases; animal models; experimental therapies;
D O I
10.1159/000089628
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Translational research has become a strategy which describes the steps from in vitro experimental therapy, its translation into experimental animals and finally to humans. However, this translation of hypotheses from one of these levels to another faces a number of difficulties which are currently of major interest for the development of therapeutics. In particular, in the previously untreatable motor neuron diseases, the steps from genes to transgenic animals and finally to the patient have proven difficult. High expectations have not met with the transfer of numerous therapies from experimental animals to men; there are many in- and outside the field which already question the value of animal models. It is the opinion of the authors that we should not dismiss the models before we have not defined generally accepted standards of protocols for therapeutic studies in experimental animals. Only if a generally agreed standardized and validated methodology in mice cannot predict the human response to therapeutics, an animal model should be abandoned. In contrast, the value of translating genetic findings to experimental animals and men is currently shown for motor proteins; in particular the functional impact of dynactin and dynein for the integrity of motor neurons of rodents and men are in the center of interest. Copyright (C) 2005 S. Karger AG, Basel
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [1] Preclinical randomized controlled multicenter trials in translational stroke research
    Amaro, Sergio
    Llull, Laura
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4
  • [2] Phase III Preclinical Trials in Translational Stroke Research: Community Response on Framework and Guidelines
    Johannes Boltze
    Daniel-Christoph Wagner
    Nils Henninger
    Nikolaus Plesnila
    Cenk Ayata
    Translational Stroke Research, 2016, 7 : 241 - 247
  • [3] Phase III Preclinical Trials in Translational Stroke Research: Community Response on Framework and Guidelines
    Boltze, Johannes
    Wagner, Daniel-Christoph
    Henninger, Nils
    Plesnila, Nikolaus
    Ayata, Cenk
    TRANSLATIONAL STROKE RESEARCH, 2016, 7 (04) : 241 - 247
  • [4] REPRINT: International, Multicenter Randomized Preclinical Trials in Translational Stroke Research It Is Time to Act
    Dirnagl, Ulrich
    Fisher, Marc
    STROKE, 2012, 43 (06) : 1453 - 1454
  • [5] International, multicenter randomized preclinical trials in translational stroke research: It's time to act
    Dirnagl, Ulrich
    Fisher, Marc
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 (06): : 933 - 935
  • [6] Cell therapy in ALS: An update on preclinical and clinical studies
    Sironi, Francesca
    De Marchi, Fabiola
    Mazzini, Letizia
    Bendotti, Caterina
    BRAIN RESEARCH BULLETIN, 2023, 194 : 64 - 81
  • [7] Preclinical models for translational sarcoma research
    Hamacher, Rainer
    Bauer, Sebastian
    CURRENT OPINION IN ONCOLOGY, 2017, 29 (04) : 275 - 285
  • [8] Translating preclinical insights into effective human trials in ALS
    DiBernardo, Allitia B.
    Cudkowicz, Merit E.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2006, 1762 (11-12): : 1139 - 1149
  • [9] Preclinical Phase III Trials in Translational Stroke Research Call for Collective Design of Framework and Guidelines
    Boltze, Johannes
    Ayata, Cenk
    Wagner, Daniel-Christoph
    Plesnila, Nikolaus
    STROKE, 2014, 45 (02) : 357 - 357
  • [10] Translational research in radiotherapy trials
    West, C.
    McKeown, S.
    BRITISH JOURNAL OF RADIOLOGY, 2006, 79 (945): : 716 - 718